
|Articles|December 30, 2013
Segment 1 - Introduction to NSCLC
Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).
Advertisement
Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC). This includes the therapeutic importance of distinguishing NSCLC by histology. Dr Sugarbaker says that adenocarcinoma, squamous cell carcinoma (SCC), and large-cell carcinoma (LCC) are all considered in the broader category of NSCLC. The therapy for each of these histologies is determined by different indicators, and then classified into stages I-IV.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access
5




